Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 9/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | TYMS | P04818 | 2/20 | 0.73 |
| ▸ | POLB | P06746 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.73 |
| ▸ | TLR4 | O00206 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | GLA | P06280 | 1/20 | 0.70 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aminopterin SCHEMBL5024596 | 1.00 | DHFR (0.75) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Aminopterin SCHEMBL29443569 | 0.99 | DHFR (0.76) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Aminopterin SCHEMBL29398079 | 0.99 | DHFR (0.76) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Aminopterin SCHEMBL20769794 | 0.99 | DHFR (0.76) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Aminopterin SCHEMBL8161477 | 0.99 | DHFR (0.76) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Aminopterin SCHEMBL9514067 | 0.99 | DHFR (0.76) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Aminopterin SCHEMBL8887 | 0.99 | DHFR (0.76) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Aminopterin SCHEMBL1626034 | 0.99 | DHFR (0.76) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Aminopterin SCHEMBL23581239 | 0.98 | DHFR (0.75) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Aminopterin SCHEMBL2387187 | 0.98 | DHFR (0.75) | DHFRKDM4EMEN1ALDH1A1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106431854-A | Method for synthesizing acrolein diethyl acetal being aminopterin sodium drug intermediate | 厦门市凯尔利信息科技有限公司 | 2017-02-22 | — | — | CN | claimed |
| CN-106431984-A | Method for synthesizing aminopterin drug intermediate cyanoacetamide | 厦门莱恩斯特信息科技有限公司 | 2017-02-22 | — | — | CN | claimed |
| CN-105541661-A | Aminopterin sodium drug intermediate cyanoacetamide synthesis method | CHENGDU DONGDIAN AIER SCIENCE AND TECH CO LTD | 2016-05-04 | — | — | CN | claimed |
| CN-105503547-A | Method for synthesizing aminopterin sodium drug intermediate acrolein diethyl acetal | CHENGDU QIANYE LONGHUA PETROLEUM ENG TECH CONSULTING CO LTD | 2016-04-20 | — | — | CN | claimed |
| CN-104127469-A | New application of olive leaf crude extract and tumor therapeutic drug combined kit thereof | SHANGHAI YUXIAN MEDICAL TECHNOLOGY CO LTD | 2014-11-05 | — | — | CN | claimed |
| CN-1923173-A | Anti-cancer drugs slow release agent comprising anticancer antibiotics and booster thereof | JINAN KANGQUAN PHARMACEUTICAL (CN) | 2007-03-07 | — | — | CN | claimed |
| CN-1857723-A | Slow released anticancer medicine preparation with both amrubicin and its synergist | KANGQUAN MEDICINE SCI TECH CO (CN) | 2006-11-08 | — | — | CN | claimed |
| CN-1634584-A | Anti-cancer medicine composition containing antimetabolite | SHANDONG LANJIN BIOENGINEERING (CN) | 2005-07-06 | — | — | CN | claimed |
| US-4925662-A | ANTITUMOR AGENT BONDED TO HUMAN IMMUNOGLOBULIN | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1990-05-15 | — | — | US | claimed |
| EP-0122132-A2 | Anti-tumour substance | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1984-10-17 | — | — | EP | claimed |
| US-4401592-A | REACTION PRODUCT OF AN ANTIBODY WITH AN ANTIBIOTIC, ANTIMETABOLIC SUBSTANCE OR ALKYLATING AGENT | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1983-08-30 | — | — | US | claimed |
| CN-112601751-B | Fused thiophene compounds | 拜欧斯瑞克斯公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-4206196-A1 | PYRIMIDINE SUBSTITUTED DERIVATIVES AS TYK2 INHIBITORS | Almirall S.A. (ES) | 2023-07-05 | — | — | EP | disclosed |
| CN-110302004-A | Device and method for ocular injection | 科尼尔赛德生物医学公司 | 2019-10-08 | — | — | CN | disclosed |
| US-20190216815-A1 | COMBINATION THERAPY COMPRISING A POLYUNSATURATED KETONE AND A FOLIC ACID PARTNER | AVEXXIN AS (NO) | 2019-07-18 | — | — | US | disclosed |
| US-4622218-A | Testicular-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1986-11-11 | — | — | US | disclosed |
| US-4584136-A | Process for preparing Estracyt compounds having a carcinostatic bound thereto | JAPAN ATOMIC ENERGY RESEARCH INSTITUTE (JP) | 1986-04-22 | — | — | US | disclosed |
| EP-0122132-A2 | Anti-tumour substance | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1984-10-17 | — | — | EP | disclosed |
| US-4401592-A | REACTION PRODUCT OF AN ANTIBODY WITH AN ANTIBIOTIC, ANTIMETABOLIC SUBSTANCE OR ALKYLATING AGENT | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1983-08-30 | — | — | US | disclosed |
| US-4315851-A | AFFINITY-CHROMATOGRAPHY PURIFIED IMMUNOGLOBULIN, ANTIBODIES,ANTIGENS OR ANTIBIOTICS | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1982-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216815-A1 | COMBINATION THERAPY COMPRISING A POLYUNSATURATED KETONE AND A FOLIC ACID PARTNER | FOLR2, MTHFD2, FOLR1 | DHFR 4/4885KDM4E 2739/4885MEN1 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.